Category: SPMS-PPMS News

Experimental SPMS Drug From Innate Therapeutics Shows Success in Early Trials

FEBRUARY 13TH, 2015  MAUREEN NEWMAN Under development at Innate Immunotherapeutics is a special drug candidate to treatsecondary progressive multiple sclerosis (SPMS). Currently, no viable therapies…

Stuart Schlossman

PPMS news – 100th patient enrolled in multiple sclerosis study

Published 12:30 am Thursday, January 22, 2015 By Emily Ford  For the Duke Translational Medicine Institute A Raleigh medical practice…

Stuart Schlossman

What are the most promising approaches to treating progressive MS?

Progressive multiple sclerosis represents a significant management challenge, so we asked three well-known researchers and clinicians to share their thoughts…

Stuart Schlossman

Secondary progressive multiple sclerosis therapeutic pipeline market review for 2014 just published

The report “Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Review, H2 2014” provides an overview of the Secondary Progressive Multiple Sclerosis…

Stuart Schlossman

The Progressive MS Alliance invites you to join an informational call to learn more about a new funding initiative just released by the Alliance.

Progressive MS Alliance The Progressive MS Alliance invites you to join an informational call to learn more about a new…

Stuart Schlossman

Primary Progressive Multiple Sclerosis Market

Transparency Market Research includes new market research report “Primary Progressive Multiple Sclerosis Market” to its huge collection of research reports.…

Stuart Schlossman

Some Astrocytes Appear to Promote Progressive MS

October 2014 Researchers have identified a key enzyme in astrocytes that turns on during the progressive stage of multiple sclerosis,…

Stuart Schlossman

Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit

October 20, 2014 THE WOODLANDS, Texas–(BUSINESS WIRE)– Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune…

Stuart Schlossman

Secondary Progressive Multiple Sclerosis (SPMS) in Australia

The MIS416 trial is a clinical research trial now enrolling patients with Secondary Progressive Multiple Sclerosis (SPMS) in Australia. Full…

Stuart Schlossman

Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova

MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in…

Stuart Schlossman

Categories

Latest Blog Posts